Bimeda announces relaunch of Oxycomplex NS Solution for Injection (POM)


Bimeda Animal Health Limited is pleased to announce the return to the Irish market of Oxycomplex NS Solution for Injection.

Oxycomplex NS Solution for Injection contains 100mg/ml of Oxytetracycline (as oxytetracycline hydrochloride) and 20mg/ml Flunixin (as flunixin meglumine); offering broad spectrum antibiotic cover together with an anti-inflammatory agent.

The product is licensed for the control and treatment of infectious diseases of cattle caused
by, or associated with, organisms sensitive to oxytetracycline, where concurrent analgesic, anti-inflammatory, anti-endotoxic or antipyretic therapy is desired. Oxycomplex NS is especially indicated for the treatment of respiratory disease (particularly that associated with Pasteurella infection) and acute mastitis (in conjunction with appropriate therapy).

Bimeda Ireland General Manager, Andrew Glynn, commented, 'with its dual-action antimicrobial and anti-inflammatory activity, Oxycomplex NS is a convenient option for veterinarians when treating pneumonia, acute mastitis and disease associated with organisms sensitive to oxytetracycline. The product is licensed for both intravenous and deep intramuscular use, and offers broad spectrum activity against Gram-negative and Gram-positive bacteria. Oxycomplex NS complements our broad range of injectables, which include antimicrobials, anti-parasitics, anti-inflammatories, hormones and vitamins.'

Oxycomplex NS Solution for Injection is a POM category product, has a 28 day meat, a 5 day milk withdrawal period and is available in a 100ml pack size.

Full product information can be found on the SPC, which is hosted on the HPRA website.
Use Medicines Responsibly.

Bimeda Launches Apple-Flavoured Flunixin Oral Past...
Bimeda Launches New Training Animation to Assist W...